依折麦布联合氟伐他汀对冠心病高危患者的强化调脂作用

摘要

目的：观察依折麦布联合氟伐他汀对冠心病高危患者的强化调脂作用。方法选择医院2014年收治的冠心病高危患者74例，随机分为观察组与对照组，各37例。两组均给予常规治疗，对照组加用2倍剂量（40 mg/d）的氟伐他汀，观察组加用1倍剂量（20 mg/d）的氟伐他汀和依折麦布(10 mg/d )，两组患者均治疗3个月。比较两组患者的临床疗效，检测超敏C反应蛋白（hs－CRP）浓度、血脂总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL－C）及低密度脂蛋白胆固醇（LDL－C）水平，计算颈动脉斑块Crouse积分，记录不良反应的发生情况。结果治疗后，观察组总有效率为75.68%，与对照组的67.57%相当（ P>0.05）；两组患者TC，LDL－C水平均较治疗前下降（ P 0. 05);the levels of TC,LDL-C and hs-CRP levels decreased in the two groups( P < 0. 05),HDL-C expres-sion levels increased( P < 0. 05),and the range of improvement in the observation groups was better than the control group( P < 0. 05);the Crouse scores of the two groups showed statistically significant difference compared with before treatment,and the decrease in the observation groups was more than the control group( P < 0. 05);the occurrence rate of adverse reaction in the observation group was 10. 81%,which was obviously lower than 21. 62% of the control group( P < 0. 05). Conclusion Ezetimibe combined with fluvastat-intins can adjust blood lipid metabolism in patients with coronary heart disease,can slow hardening of the arteries process to a certain extent,at the same time has no serious adverse reaction,is safer and worthy of clinical promotion.